Nipocalimab

Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases[1][2][3].

Product Specifications

CAS Number

[2211985-36-1]

Product Name Alternative

M281

UNSPSC

12352203

Target

Fc Receptor (FcR)

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nipocalimab.html

Purity

99.0

Solubility

H2O

Smiles

[Nipocalimab]

Molecular Weight

(142.12 kDa)

References & Citations

[1]James S Castleman, et al. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol. 2021 Feb;192 (3) :425-432.|[2]Marinos C Dalakas, et al. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021 Feb 26;14:1756286421997381.|[3]Ling L E, et al. Selective targeting of FcRn and IgG clearance by nipocalimab preserves key immune functions. Hematology, Transfusion and Cell Therapy, 2022, 44: S13.